Overview

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Leipzig
Collaborators:
Amgen
Celgene Corporation
Mundipharma Pte Ltd.
Treatments:
Bendamustine Hydrochloride
Lenalidomide
Prednisone
Thalidomide